Relay Therapeutics Inc. Insider Trading

RLAY

Last 12 months

Insiders sold $12.8M and bought nothing on the open market.

93% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jul 2020.

Net open-market

−$12.8M

0 buys · 30 sales

Under a 10b5-1 plan

93%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Jul 2020

Jul 20, 2020

Get an email when RLAY's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 28	Peter Rahmer See remarks	SoldNo plan	753	$18.62	14K	0.3%	Form 4
Oct 28	Donald A Bergstrom President, R&D	SoldNo plan	2,252	$18.62	42K	0.6%	Form 4
Oct 28	Thomas Catinazzo Chief Financial Officer	SoldNo plan	1,469	$18.62	27K	1.4%	Form 4
Oct 7	Sanjiv Patel President and CEO	Sold10b5-1 plan	48,199	$18.10	872K	3.4%	Form 4
Oct 6	Thomas Catinazzo Chief Financial Officer	Sold10b5-1 plan 2 parts	17,717	$18.59 average	329K	14%	Form 4
Sep 8	Donald A Bergstrom President, R&D	Sold10b5-1 plan	8,530	$18.97	162K	2.1%	Form 4
Sep 8	Thomas Catinazzo Chief Financial Officer	Sold10b5-1 plan	17,717	$18.94	336K	13%	Form 4
Sep 8	Sanjiv Patel President and CEO	Sold10b5-1 plan	48,199	$18.94	913K	3.3%	Form 4
Aug 26	Peter Rahmer See remarks	Sold10b5-1 plan	4,508	$20.03	90K	2.0%	Form 4
Aug 25	SB Investment Advisers (uk) LTD Large holder	SoldNo plan	6,000,000	$19.40	$116M	22%	Form 4
Aug 17	Sanjiv Patel President and CEO	Sold10b5-1 plan	48,199	$20.33	980K	3.2%	Form 4
Aug 14	Thomas Catinazzo Chief Financial Officer	Sold10b5-1 plan	17,717	$19.74	350K	11%	Form 4
Jul 28	Thomas Catinazzo Chief Financial Officer	SoldNo plan	1,459	$18.61	27K	0.9%	Form 4
Jul 28	Peter Rahmer See remarks	SoldNo plan	748	$18.61	14K	0.3%	Form 4
Jul 28	Donald A Bergstrom President, R&D	SoldNo plan	2,237	$18.61	42K	0.5%	Form 4
Jul 7	Sanjiv Patel President and CEO	Sold10b5-1 plan	48,199	$19.58	944K	3.1%	Form 4
Jul 6	Donald A Bergstrom President, R&D	Sold10b5-1 plan	8,660	$18.71	162K	2.1%	Form 4
Jul 6	Thomas Catinazzo Chief Financial Officer	Sold10b5-1 plan	17,717	$18.69	331K	10.0%	Form 4
Jun 30	Peter Rahmer See remarks	Sold10b5-1 plan	50,000	$19.09	955K	18%	Form 4
Jun 22	Thomas Catinazzo Chief Financial Officer	Sold10b5-1 plan 4 parts	187,163	$16.97 average	$3.18M	51%	Form 4
Jun 22	Donald A Bergstrom President, R&D	Sold10b5-1 plan	93,456	$16.94	$1.58M	18%	Form 4
May 14	Thomas Catinazzo Chief Financial Officer	Sold10b5-1 plan	17,717	$12.86	228K	8.3%	Form 4
Apr 28	Thomas Catinazzo Chief Financial Officer	SoldNo plan	972	$14.79	14K	0.5%	Form 4
Apr 28	Peter Rahmer See remarks	SoldNo plan	753	$14.79	11K	0.3%	Form 4
Apr 28	Donald A Bergstrom President, R&D	SoldNo plan	1,490	$14.79	22K	0.4%	Form 4
Apr 7 – 9	Thomas Catinazzo Chief Financial Officer	Sold10b5-1 plan 2 parts	19,517	$13.19 average	257K	8.4%	Form 4
Mar 9	Thomas Catinazzo Chief Financial Officer	Sold10b5-1 plan	17,717	$10.06	178K	7.1%	Form 4
Jan 27 – 28	Donald A Bergstrom President, R&D	SoldNo plan 2 parts	21,581	$7.72 average	167K	4.9%	Form 4
Jan 27 – 28	Peter Rahmer See remarks	SoldNo plan 2 parts	13,038	$7.71 average	100K	4.5%	Form 4
Jan 27 – 28	Thomas Catinazzo Chief Financial Officer	SoldNo plan 2 parts	15,515	$7.71 average	120K	5.9%	Form 4
Jan 6	Sanjiv Patel President and CEO	SoldNo plan	43,168	$7.82	338K	2.7%	Form 4
Nov 3, 2025	Sanjiv Patel President and CEO	SoldNo plan	62,073	$7.00	435K	3.8%	Form 4
Oct 28, 2025 – Oct 29, 2025	Peter Rahmer See remarks	SoldNo plan 2 parts	40,529	$7.40 average	300K	11%	Form 4
Oct 28, 2025	Thomas Catinazzo Chief Financial Officer	SoldNo plan	21,664	$7.29	158K	6.5%	Form 4
Oct 28, 2025	Donald A Bergstrom President, R&D	SoldNo plan	30,897	$7.29	225K	5.6%	Form 4
Jul 28, 2025 – Jul 29, 2025	Peter Rahmer See remarks	SoldNo plan 2 parts	17,083	$3.68 average	63K	4.3%	Form 4
Jul 28, 2025 – Jul 29, 2025	Thomas Catinazzo Chief Financial Officer	SoldNo plan 2 parts	20,081	$3.69 average	74K	5.7%	Form 4
Jul 28, 2025 – Jul 29, 2025	Donald A Bergstrom President, R&D	SoldNo plan 2 parts	30,770	$3.69 average	113K	5.3%	Form 4
Jul 28, 2025 – Jul 29, 2025	Brian Adams Chief Legal Officer	SoldNo plan 2 parts	19,913	$3.68 average	73K	5.1%	Form 4
Jul 9, 2025	Sanjiv Patel President and CEO	SoldNo plan 2 parts	61,379	$3.57 average	219K	3.6%	Form 4

Oct 28No plan
Peter Rahmer
See remarks · sold 753 at $18.62
14K
0.3% of stake
Oct 28No plan
Donald A Bergstrom
President, R&D · sold 2,252 at $18.62
42K
0.6% of stake
Oct 28No plan
Thomas Catinazzo
Chief Financial Officer · sold 1,469 at $18.62
27K
1.4% of stake
Oct 710b5-1 plan
Sanjiv Patel
President and CEO · sold 48,199 at $18.10
872K
3.4% of stake
Oct 610b5-1 plan
Thomas Catinazzo
Chief Financial Officer · sold 17,717 at avg $18.59
329K
14% of stake
Sep 810b5-1 plan
Donald A Bergstrom
President, R&D · sold 8,530 at $18.97
162K
2.1% of stake
Sep 810b5-1 plan
Thomas Catinazzo
Chief Financial Officer · sold 17,717 at $18.94
336K
13% of stake
Sep 810b5-1 plan
Sanjiv Patel
President and CEO · sold 48,199 at $18.94
913K
3.3% of stake
Aug 2610b5-1 plan
Peter Rahmer
See remarks · sold 4,508 at $20.03
90K
2.0% of stake
Aug 25No plan
SB Investment Advisers (uk) LTD
Large holder · sold 6,000,000 at $19.40
$116M
22% of stake
Aug 1710b5-1 plan
Sanjiv Patel
President and CEO · sold 48,199 at $20.33
980K
3.2% of stake
Aug 1410b5-1 plan
Thomas Catinazzo
Chief Financial Officer · sold 17,717 at $19.74
350K
11% of stake
Jul 28No plan
Thomas Catinazzo
Chief Financial Officer · sold 1,459 at $18.61
27K
0.9% of stake
Jul 28No plan
Peter Rahmer
See remarks · sold 748 at $18.61
14K
0.3% of stake
Jul 28No plan
Donald A Bergstrom
President, R&D · sold 2,237 at $18.61
42K
0.5% of stake
Jul 710b5-1 plan
Sanjiv Patel
President and CEO · sold 48,199 at $19.58
944K
3.1% of stake
Jul 610b5-1 plan
Donald A Bergstrom
President, R&D · sold 8,660 at $18.71
162K
2.1% of stake
Jul 610b5-1 plan
Thomas Catinazzo
Chief Financial Officer · sold 17,717 at $18.69
331K
10.0% of stake
Jun 3010b5-1 plan
Peter Rahmer
See remarks · sold 50,000 at $19.09
955K
18% of stake
Jun 2210b5-1 plan
Thomas Catinazzo
Chief Financial Officer · sold 187,163 at avg $16.97
$3.18M
51% of stake
Jun 2210b5-1 plan
Donald A Bergstrom
President, R&D · sold 93,456 at $16.94
$1.58M
18% of stake
May 1410b5-1 plan
Thomas Catinazzo
Chief Financial Officer · sold 17,717 at $12.86
228K
8.3% of stake
Apr 28No plan
Thomas Catinazzo
Chief Financial Officer · sold 972 at $14.79
14K
0.5% of stake
Apr 28No plan
Peter Rahmer
See remarks · sold 753 at $14.79
11K
0.3% of stake
Apr 28No plan
Donald A Bergstrom
President, R&D · sold 1,490 at $14.79
22K
0.4% of stake
Apr 7 – 910b5-1 plan
Thomas Catinazzo
Chief Financial Officer · sold 19,517 at avg $13.19
257K
8.4% of stake
Mar 910b5-1 plan
Thomas Catinazzo
Chief Financial Officer · sold 17,717 at $10.06
178K
7.1% of stake
Jan 27 – 28No plan
Donald A Bergstrom
President, R&D · sold 21,581 at avg $7.72
167K
4.9% of stake
Jan 27 – 28No plan
Peter Rahmer
See remarks · sold 13,038 at avg $7.71
100K
4.5% of stake
Jan 27 – 28No plan
Thomas Catinazzo
Chief Financial Officer · sold 15,515 at avg $7.71
120K
5.9% of stake
Jan 6No plan
Sanjiv Patel
President and CEO · sold 43,168 at $7.82
338K
2.7% of stake
Nov 3, 2025No plan
Sanjiv Patel
President and CEO · sold 62,073 at $7.00
435K
3.8% of stake
Oct 28, 2025 – Oct 29, 2025No plan
Peter Rahmer
See remarks · sold 40,529 at avg $7.40
300K
11% of stake
Oct 28, 2025No plan
Thomas Catinazzo
Chief Financial Officer · sold 21,664 at $7.29
158K
6.5% of stake
Oct 28, 2025No plan
Donald A Bergstrom
President, R&D · sold 30,897 at $7.29
225K
5.6% of stake
Jul 28, 2025 – Jul 29, 2025No plan
Peter Rahmer
See remarks · sold 17,083 at avg $3.68
63K
4.3% of stake
Jul 28, 2025 – Jul 29, 2025No plan
Thomas Catinazzo
Chief Financial Officer · sold 20,081 at avg $3.69
74K
5.7% of stake
Jul 28, 2025 – Jul 29, 2025No plan
Donald A Bergstrom
President, R&D · sold 30,770 at avg $3.69
113K
5.3% of stake
Jul 28, 2025 – Jul 29, 2025No plan
Brian Adams
Chief Legal Officer · sold 19,913 at avg $3.68
73K
5.1% of stake
Jul 9, 2025No plan
Sanjiv Patel
President and CEO · sold 61,379 at avg $3.57
219K
3.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RLAY, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with RLAY

CompareIntrinsic value

CRBUCaribou Biosciences, Inc.

$0.44-3.27%10

RVMDRevolution Medicines Inc.

$199.21+2.56%10

XFORX4 Pharmaceuticals Inc.

$3.24+2.21%20

ELUTElutia Inc.

$0.76-6.52%20

LCTXLineage Cell Therapeutics Inc.

$1.03+1.98%10

SRZNSurrozen, Inc.

$31.65+5.08%10

CRSPCrispr Therapeutics AG

$51.78+3.57%40

TCRXTScan Therapeutics Inc.

$0.21+11.11%10

Held by ETFs

RLAY is in 59 US ETFs. The largest of them, with RLAY's weight in each:

Spot a number that looks wrong? Check it in RLAY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RLAY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.